Compare Mesoblast Limited (MESO) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Sibanye Stillwater Ltd — how do they compare? Mesoblast Limited trades at $16.28 (market cap $2.17B), while Sibanye Stillwater Ltd trades at $8.33 (market cap $5.66B). The key difference: Sibanye Stillwater Ltd is far larger — about 2.6× Mesoblast Limited's market cap, and Sibanye Stillwater Ltd pays a 3.89% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | SBSW | |
|---|---|---|
Market Cap | $2.17B | $5.66B |
Sector | Technology | Basic Materials |
52-Week High | $20.96 | $21.12 |
52-Week Low | $12.88 | $7.27 |
Enterprise Value | $2.17B | $7.28B |
Dividend Yield | — | 3.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Sibanye Stillwater (SBSW) trades at $8.02, up 0.25% on the day, with technical indicators showing a bearish trend. The company reported a net loss of $7.30 billion in 2024, though revenue remained stable at $112.13 billion. Recent news highlights management's focus on debt reduction and operational improvements, with Seeking Alpha noting a 5x YoY EBITDA surge driven by strong PGM and gold prices as of July 3, 2026.
The stock presents a high-risk opportunity with a consensus price target of $14.25, implying significant upside, but faces headwinds from negative profitability metrics and volatile commodity prices. Investors should weigh the potential turnaround against ongoing operational challenges and macroeconomic risks in the mining sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
